QDEL QuidelOrtho Corp

CIK 0001906324 50 ready 8-Ks latest June 23, 2026, 4:04 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (2)

Ready 8-Ks 50

Latest filing June 23, 2026, 4:04 PM ET

Top materiality 0.85

Event mix earnings ×23 · leadership ×15 · other_material ×6

Sentiment 11 pos · 8 neg · 31 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for QDEL

Highest-materiality recent filing

QuidelOrtho Q1 revenue $711M, GAAP loss $25.50/share; suspends 2024 guidance after new CEO

May 8, 2024, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01 ◈ Earnings Releases

Total revenue $711M, down 16% YoY; ex-COVID revenue grew 5% as reported (6% constant currency).
GAAP diluted loss per share $25.50 from $1.74B goodwill impairment; adjusted EPS $0.44 vs $1.80.

Read filing →

June 23, 2026, 4:04 PM ET leadership materiality 0.60 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

QuidelOrtho appoints Micah Young as CFO effective July 6, 2026

Micah Young appointed CFO, effective July 6, 2026; succeeds Joseph Busky who is retiring.
May 5, 2026, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01 ◈ Earnings Releases

QuidelOrtho Q1 net loss $92M; revenue $620M; cuts full-year guidance

GAAP net loss $92M ($1.35 diluted loss per share); adjusted diluted EPS loss $0.04; revenue $620M.
April 15, 2026, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01 ◈ Earnings Releases

QuidelOrtho prelim Q1 rev $615-620M; weaker respiratory season, China headwinds

Prelim Q1 2026 revenue of $615-$620M; U.S. flu-like illness visits down ~30% YoY.
February 13, 2026, 6:59 PM ET leadership materiality 0.65 neutral item 5.02

CFO Joseph M. Busky to retire effective June 30, 2026

Joseph M. Busky notified QuidelOrtho of his retirement on February 9, 2026.
February 11, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

QuidelOrtho reports FY25 revenue $2.73B, adjusted EBITDA $597M; guides FY26 revenue $2.7-2.9B

FY25 total revenue $2.73B in line with guidance; Labs revenue +6% as reported, non-respiratory +5% ex Donor Screening.
November 10, 2025, 6:59 PM ET earnings materiality 0.80 positive item 7.01 item 9.01

QuidelOrtho Q3: revenue $700M, adj. EBITDA margin 25%, core growth 5% YoY

Total revenue $700M; core revenue (ex-COVID/Donor Screening) grew 5% as reported.
November 5, 2025, 6:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

QuidelOrtho Q3 revenue $700M (-4% YoY); GAAP loss $10.78/sh on $701M impairment; Adj EPS $0.80

Total revenue $700M, down 4% YoY; non-respiratory revenue up 5% as reported, 6% constant currency ex-Donor Screening.
August 21, 2025, 7:59 PM ET debt materiality 0.65 positive item 1.01 item 2.03 item 8.01 item 9.01 ◈ Debt Financings ×4

QuidelOrtho refinances with $1.15B Term Loan A, $1.45B Term Loan B, $700M revolver

New credit facility includes $1.15B 5-yr Term Loan A, $1.45B 7-yr Term Loan B, $700M revolver, and $100M delayed draw Term Loan A (undrawn).
August 5, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

QuidelOrtho reports Q2 2025 adjusted EPS of $0.12 vs loss of ($0.07); reaffirms FY guidance

Q2 revenue $614M (-3.6% YoY); Labs revenue +4% as reported, but respiratory revenue fell 20% to $47M on lower COVID-19 sales.
May 7, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01

QuidelOrtho Q1 revenue $693M, +5% ex-COVID/Donor; adjusted EPS $0.74 vs $0.44 YoY

Total revenue $693M, -3% reported due to lower COVID/Donor; ex-COVID/Donor +5% as reported and +6% constant currency.
March 4, 2025, 6:59 PM ET other material materiality 0.60 neutral item 4.01 item 9.01 ◈ Auditor Changes ×2

QuidelOrtho appoints KPMG as auditor, dismisses EY; material weaknesses disclosed

Audit Committee selected KPMG as independent auditor for FY 2025, dismissing EY effective Feb 28, 2025, after competitive process.
February 12, 2025, 6:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

QuidelOrtho Q4 GAAP loss $2.28/sh; FY2024 rev $2.78B; guides FY25 rev $2.60-$2.81B, adj EBITDA margin 22%

Q4 GAAP diluted loss per share $2.28 vs EPS $0.10 prior year; adjusted EPS $0.63 vs $1.17.
November 21, 2024, 6:59 PM ET other material materiality 0.70 neutral item 5.02 item 8.01 item 9.01

Carlyle sells 8.26M QuidelOrtho shares at $35.31; two Carlyle directors resign

Carlyle Partners VI sells 8,260,183 QDEL shares at $35.31/share; company receives no proceeds.
November 7, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

QuidelOrtho Q3 GAAP net loss $20M ($0.30 EPS); revenue $727M; reinstates 2024 guidance

Revenue $727M vs $744M YoY; Labs revenue grew 4% as reported (5% constant currency).
July 31, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

QuidelOrtho Q2 2024: revenue $637M, GAAP diluted loss ($2.20)/share

Total revenue $637M, down 4% YoY; lower COVID-19 revenue was primary driver.
May 8, 2024, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01 ◈ Earnings Releases

QuidelOrtho Q1 revenue $711M, GAAP loss $25.50/share; suspends 2024 guidance after new CEO

Total revenue $711M, down 16% YoY; ex-COVID revenue grew 5% as reported (6% constant currency).
May 7, 2024, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×4

QuidelOrtho appoints Brian J. Blaser as CEO effective May 6, 2024

Blaser, ex-Abbott EVP Diagnostic Products, replaces interim CEO Michael Iskra and interim President Robert Bujarski.
February 21, 2024, 6:59 PM ET leadership materiality 0.70 neutral item 5.02 ◈ executive_change ×4

QuidelOrtho terminates CEO Bryant, appoints Iskra as interim CEO

Douglas Bryant terminated as President and CEO effective Feb 21, 2024; he also resigns from the Board.
February 13, 2024, 6:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01 ◈ Earnings Releases

QuidelOrtho Q4 revenue $743M (-14% YoY); GAAP EPS $0.10, adj. EPS $1.17; FY24 guidance issued

Q4 revenue $743M vs $867M YoY; non-respiratory +9%, respiratory -49%.
November 1, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases ×2

QuidelOrtho Q3 revenue $744M, GAAP loss $0.19/sh, adj EPS $0.90; maintains FY guidance

Total revenue $744.0M, down from $783.8M YoY; respiratory revenue declined 21% as anticipated.
October 12, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

QuidelOrtho preliminary Q3 revenue $738-744M; beats on early respiratory demand

Total revenue $738-744M vs prior expectations; non-respiratory $557-560M, respiratory $181-184M.
August 8, 2023, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

QuidelOrtho Q2 revenue $665M, GAAP loss $(0.80)/share, adj. EPS $0.26; respiratory revenue down 74%

Revenue $665.1M (+8% reported) but down 26% on supplemental combined basis vs Q2 2022.
May 3, 2023, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases

Q1 revenue $846.1M, down 16%; GAAP EPS $0.73, adjusted EPS $1.80

Total revenue $846.1M, down 16% YoY; non-respiratory up 5% on supplemental combined basis.
April 13, 2023, 7:59 PM ET earnings materiality 0.60 positive item 2.02 item 9.01 ◈ Earnings Releases

QuidelOrtho pre-announces Q1 revenue $840-850M; non-respiratory grows 5-7%

Total preliminary Q1 revenue $840-850M; respiratory $262-267M including COVID-19 $212-217M.
February 15, 2023, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases ×2

QuidelOrtho reports Q4 2022 revenue $866.5M, GAAP EPS $0.45; supplemental adjusted EPS $1.76 down 66% YoY

Q4 GAAP EPS $0.45 vs $6.85 prior year; supplemental adjusted EPS $1.76, down 66% YoY.
January 6, 2023, 6:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

QuidelOrtho Q4 2022 preliminary revenue $853-868M; non-COVID rev up 18% proforma constant currency

Preliminary Q4 total revenue $853M-$868M; COVID $124M-$134M; non-COVID $729M-$734M.
November 2, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

QuidelOrtho Q3 2022: revenue $783.8M (-21.8% combined const. currency); GAAP EPS $0.28; adjusts guidance up

Revenue $783.8M, +54% reported; supplemental combined revenue -21.8% constant currency; ex-COVID +3.0% (underlying +6.0%).
October 12, 2022, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

QuidelOrtho reports preliminary Q3 2022 revenue $782-785M; COVID revenue ~$171M

Total revenue expected $782M-$785M; non-COVID product revenue $611M-$614M.
August 17, 2022, 7:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

QuidelOrtho authorizes $300M share repurchase over two years; cites confidence in cash generation

Board authorized repurchase of up to $300M of common stock through August 17, 2024.
August 10, 2022, 7:59 PM ET other material materiality 0.60 neutral item 2.01 item 9.01

QuidelOrtho reports pro forma combined revenue of $2.4B and net income of $489.9M for H1 2022

Pro forma combined revenue for six months ended July 3, 2022: $2.4B; net income $489.9M; diluted EPS $7.22.
August 4, 2022, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

QuidelOrtho Q2 supplemental combined revenue $898.5M, adj EPS $2.12, up 123% YoY

GAAP revenue $613.4M (+247% as reported) from business combination with Ortho closed May 27, 2022.

Executive changes

Departed

Joseph M. Busky

Chief Financial Officer

QDEL · QuidelOrtho Corp

Effective: 2026-07-06
Successor: Micah Young
Filed: June 23, 2026, 4:04 PM ET

Mr. Young will succeed Joseph M. Busky, who previously announced his plans to retire

Appointed

Micah Young

Chief Financial Officer

QDEL · QuidelOrtho Corp

Effective: 2026-07-06
Filed: June 23, 2026, 4:04 PM ET

The Board of Directors of QuidelOrtho Corporation (the “Company”) has appointed Micah Young to serve as the Company’s Chief Financial Officer and principal financial officer, effective as of July 6, 2026

Appointed

Philip McLellan

Chief Operations Officer

QDEL · QuidelOrtho Corp

Effective: 2024-11-15
Filed: November 18, 2024, 6:59 PM ET

the Company appointed Philip McLellan to serve as the Company’s Chief Operations Officer (“COO”), effective November 15, 2024.

Role change

Joseph M. Busky

Chief Financial Officer

QDEL · QuidelOrtho Corp

Effective: 2024-11-18
Filed: November 18, 2024, 6:59 PM ET

Joseph M. Busky, the Company’s Chief Financial Officer, assuming additional responsibilities, including oversight of the Company’s Information Technology function, on November 18, 2024

Appointed

Philip McLellan

Chief Operations Officer

QDEL · QuidelOrtho Corp

Effective: 2024-11-15
Filed: November 8, 2024, 6:59 PM ET

In addition, the Company appointed Philip McLellan to serve as the Company’s Chief Operations Officer, effective as of the Effective Date.

Departed

Robert J. Bujarski

Executive Vice President and Chief Operating Officer

QDEL · QuidelOrtho Corp

Effective: 2024-11-15
Successor: Philip McLellan
Filed: November 8, 2024, 6:59 PM ET

The Company determined to terminate the employment of Michael S. Iskra, the Company’s Executive Vice President (“EVP”) and Chief Commercial Officer, and Robert J. Bujarski, the Company’s EVP and Chief Operating Officer, each effective November 15, 2024 (the “Effective Date”).

Departed

Michael S. Iskra

Executive Vice President and Chief Commercial Officer

QDEL · QuidelOrtho Corp

Effective: 2024-11-15
Filed: November 8, 2024, 6:59 PM ET

The Company determined to terminate the employment of Michael S. Iskra, the Company’s Executive Vice President (“EVP”) and Chief Commercial Officer, and Robert J. Bujarski, the Company’s EVP and Chief Operating Officer, each effective November 15, 2024 (the “Effective Date”).

Appointed

Brian J. Blaser

President and Chief Executive Officer

QDEL · QuidelOrtho Corp

Effective: 2024-05-06
Filed: May 7, 2024, 7:59 PM ET

The Board of Directors (the “Board”) of QuidelOrtho Corporation (the “Company”) has appointed Brian J. Blaser to serve as the Company’s President and Chief Executive Officer, effective as of May 6, 2024 (the “Effective Date”).

Role change (interim)

Robert J. Bujarski

Interim President

QDEL · QuidelOrtho Corp

Effective: 2024-05-06
Successor: Brian J. Blaser
Filed: May 7, 2024, 7:59 PM ET

each of Michael S. Iskra, who served as the Company’s Interim Chief Executive Officer, and Robert J. Bujarski, who served as the Company’s Interim President, stepped down from these interim positions.

Appointed

Brian J. Blaser

director

QDEL · QuidelOrtho Corp

Effective: 2024-05-15
Filed: May 7, 2024, 7:59 PM ET

In addition, effective as of May 15, 2024, the Board expanded its size from ten to eleven directors and appointed Mr. Blaser to serve as a director until the Company’s 2025 Annual Meeting of Stockholders.

Role change (interim)

Michael S. Iskra

Interim Chief Executive Officer

QDEL · QuidelOrtho Corp

Effective: 2024-05-06
Successor: Brian J. Blaser
Filed: May 7, 2024, 7:59 PM ET

each of Michael S. Iskra, who served as the Company’s Interim Chief Executive Officer, and Robert J. Bujarski, who served as the Company’s Interim President, stepped down from these interim positions.

Appointed (interim)

Michael S. Iskra

Interim Chief Executive Officer

QDEL · QuidelOrtho Corp

Effective: 2024-02-21
Filed: February 21, 2024, 6:59 PM ET

the Board also appointed Michael S. Iskra to serve as the Company’s Interim Chief Executive Officer and Robert J. Bujarski to serve as the Company’s Interim President, each effective February 21, 2024.

Earnings & guidance

2026-Q1 EPS reported -$1.35 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event earnings

11 positive 8 negative 31 neutral

source · QDEL on sec.gov